Polycarp Omara
ID: UNCST-2022-R011110
|
INSTRUCTIONAL SUPERVISION AND TEACHER COMPETENCE ENHANCEMENT IN SECONDARY SCHOOLS IN ARUA, UGANDA
REFNo: SS1598ES
To propose teacher competence profile for secondary school teachers in Uganda.,To examine the relationship between non-directive supervision and teacher competence enhancement in secondary schools in greater Arua.,To examine the relationship between collaborative supervision and teacher competence enhancement in secondary schools in greater Arua.,To establish the relationship between directive supervision and teacher competence enhancement in secondary schools in greater Arua. ,To explore the status of teacher competence in secondary schools in Arua, Uganda.,To establish the different dimensions of instructional supervision employed in secondary schools in Arua, Uganda.,This study aims to explore the impact of instructional supervision on the enhancement of teacher competence in secondary schools in Arua, Uganda.,
|
Uganda |
2023-02-13 11:12:24 |
2026-02-13 |
Social Science and Humanities |
Non-Clinical Trial |
Degree Award |
|
Maxensia owor
ID: UNCST-2021-R014003
|
IMPAACT 2036: Phase I/II Study of the Safety, Tolerability, Acceptability, and Pharmacokinetics of Oral and Long-Acting Injectable Cabotegravir and Rilpivirine in Virologically Suppressed Children Living with HIV-1, Two to Less Than 12 Years of Age. Version 1.0, 22 September 2022. DAIDS study protocol ID: 38932
REFNo: HS2599ES
iii. Cohort 2: To describe the maintenance of viral suppression and immunologic activity of 48 weeks of CAB + RPV (oral and injectable) or 44 weeks of CAB LA + RPV LA (injectable only),iv. Cohort 2: To describe HIV-1 genotypes and phenotypes for children who experience virologic failure during 48 weeks of CAB + RPV (oral and injectable) or during 44 weeks of CAB LA + RPV LA (injectable only),ii. Cohort Cohort 2: To describe the safety and repeat-dose pharmacokinetics of 48 weeks of CAB + RPV (oral and injectable) or 44 weeks of CAB LA + RPV LA (injectable only),i. Cohort 2: To describe tolerability and acceptability of 48 weeks of CAB + RPV (oral and injectable) and 44 weeks of CAB LA + RPV LA (injectable only),ii Cohort 1: To assess the safety of the oral lead-in of CAB + RPV, and the safety of CAB + RPV (oral and injectable) through Week 24,i.Cohort 1: To describe the repeat-dose pharmacokinetics of CAB + RPV (oral and injectable) through Week 24,
|
Uganda |
2023-02-13 11:10:13 |
2026-02-13 |
Medical and Health Sciences |
Clinical Trial |
Non-degree Award |
|
Josphat Muchangi Martin
ID: UNCST-2022-R010507
|
Impact of the intervention ‘Financial Inclusion Improves Sanitation and Health 2022-2024’. A randomized controlled trial in Kenya and Uganda
REFNo: SS1587ES
To determine the cost-effectiveness of the FINISH model (creating earning opportunities, job market participation) and amount of leverage funds generated. ,To explore the perspectives, attitudes, and practices of various stakeholders (communities, governments, entrepreneurs, and financiers) regarding the FINISH model.,To estimate the impact of the FINISH model on health (diarrhoea occurrence, hygienic behaviour) and social (school attendance, sanitation) outcomes. ,To evaluate the impacts of the FINISH interventions in Kenya and Uganda.,
|
Kenya |
2023-02-13 11:06:11 |
2026-02-13 |
Social Science and Humanities |
Non-Clinical Trial |
Non-degree Award |
|
Denis Bwayo
ID:
|
Risk factors, genetics and mortality among patients with dilated cardiomyopathy in Uganda
REFNo: HS2444ES
1. To investigate risk factors, genetics, and moratlity among patients diagnosed with DCM in Uganda Delete
2.To determine the underlying genetics and inheritance characteristics of DCM in Uganda Delete
3. To determine the incidence and predictors of all-cause mortality 12 months after DCM diagnosis in Uganda
|
Uganda |
2023-02-13 11:04:24 |
2026-02-13 |
Medical and Health Sciences |
Non-Clinical Trial |
Degree Award |
|
Victoria Nankabirwa
ID: UNCST-2021-R011871
|
Use of the Global Scale for Early Development (GSED) within Preventing Infant Malnutrition with Early Supplementation (PRIMES) Trial
REFNo: HS2263ES
1) To obtain preliminary estimates of the correlation between Global Scale for Early Development (GSED) scores and MRI findings (total brain and white matter volumes) in infants at 6 and 12 months of age.
2) To assess user feedback about the Hyperfine LF MRI device.
3) To determine whether the Hyperfine LF MRI device is feasible and acceptable among healthcare personnel and caregivers of infants undergoing LF MRI.
|
Uganda |
2023-02-13 11:01:02 |
2026-02-13 |
Medical and Health Sciences |
Non-Clinical Trial |
Non-degree Award |
.jpg)
|
Winnie Muyindike R
ID: UNCST-2021-R013558
|
A Randomized Clinical Trial to Evaluate Solutions for the Management of Virologic Failure for Individuals on TLD in Sub-Saharan Africa.(RESOLVE)
REFNo: HS2620ES
Aim 2: Use simulation modeling to examine the clinical impact, costs, and cost-effectiveness of strategies to improve viral suppression after virologic failure on TLD. We will populate the previously validated Cost-Effectiveness of Preventing AIDS Complications-International (CEPAC-I) model with the novel clinical trial data from Aim 1 to project long-term clinical outcomes and cumulative lifetime costs. We will then compare the cost-effectiveness of the three strategies evaluated in Aim 1 for addressing virologic failure among people treated with first-line TLD in Uganda or South Africa. ,Aim 1: Conduct a randomized clinical trial to determine the optimal strategy for management of virologic failure on first-line TLD in SSA. We will recruit 648 adolescents and adults with two viral loads >1,000 copies/mL while on first-line TLD for at least 12 months, who are in care at one of six public-sector HIV clinics in Uganda or South Africa. We will randomize participants to one of the following strategies, stratified by clinic and prior NNRTI-exposure: a) Maintenance on TLD with switch to protease inhibitor (PI)-based second-line ART if virologic failure persists past six months; b) Individualized Care, with regimen choice based on results of genotypic resistance tests and urine tenofovir assays; or c) Immediate Switch to PI-based second-line ART. The primary outcome will be viral suppression (<50 copies/mL) at 48 weeks post-enrollment using the FDA snapshot definition. We hypothesize that rates of viral suppression at 48 weeks will be higher in the Individualized Care arm than in the Maintenance on TLD and Immediate Switch arms.,
|
Uganda |
2023-02-09 11:06:56 |
2026-02-09 |
Medical and Health Sciences |
Clinical Trial |
Non-degree Award |
|
Bruno Sserunkuuma
ID:
|
PREVALENCE AND FACTORS ASSOCIATED WITH ADVERSE MATERNAL OUTCOMES OF SPINAL INDUCED HYPOTESION AMONG WOMEN UDERGOING CEASAREAN DELIVERIES AT MBARARA REGIONAL REFERRAL HOSPITAL.
REFNo: HS2562ES
General objective.
To determine the prevalence and factors associated with adverse maternal outcome of spinal induced hypotension among women undergoing caesarean deliveries at Mbarara Regional Referral Hospital
Specific objectives
1.To determine the prevalence of mothers that develop spinal induced hypotension undergoing caesarean deliveries at Mbarara Regional Referral Hospital.
2.To determine the factors associated with spinal induced hypotension among mothers undergoing caesarean deliveries at Mbarara Regional Referral Hospital
3.To describe the adverse maternal outcomes among women with spinal induced hypotension
|
Uganda |
2023-02-07 11:14:38 |
2026-02-07 |
Medical and Health Sciences |
Non-Clinical Trial |
Degree Award |
|
DIANA NABUKENYA KASOZI
ID:
|
TIME TO TREATMENT INITIATION AMONG PATIENTS TREATED FOR DR-TB IN UGANDA
REFNo: HS2653ES
1. To determine the socio-demographic factors associated with drug-resistant tuberculosis (DR-TB) treatment delay among DR-TB patients in order to achieve a successful or unsuccessful treatment outcome in Uganda.
2. To investigate what clinical factors associated with DR-TB treatment delay among DR-TB patients in order to attain a successful or unsuccessful treatment outcome in Uganda.
3. Describe the structural factors associated with DR-TB treatment delay among DR-TB patients in order to achieve a successful or unsuccessful treatment outcome in Uganda.
4. To estimate the mean and median time to DR-TB treatment from the time of DR-TB diagnosis for patients on DR-TB treatment in Uganda.
|
Uganda |
2023-02-06 17:25:58 |
2026-02-06 |
Medical and Health Sciences |
Non-Clinical Trial |
Degree Award |
|
Nixon Niyonzima
ID: UNCST-2020-R014577
|
The Impact of HIV on the Breast Cancer Tumor Microenvironment
REFNo: HS2651ES
Compare the molecular profile of breast cancer tissue and blood using targeted sequencing from HIV+ women and HIV- women to identify potential HIV-associated features driving increased tumor aggressiveness.,Assess if the presence, spatial distribution, and/or the cellular phenotype of immune cells in the breast TME are consistent with HIV- associated immune dysfunction in WLWH compared to HIV- women,Identify features of HIV-associated immune dysfunction in blood and tumor tissue from WLWH with breast cancer that could promote tumorigenesis and progression.,
|
Uganda |
2023-02-06 17:24:00 |
2026-02-06 |
Medical and Health Sciences |
Non-Clinical Trial |
Non-degree Award |
|
Shannon McMorrow
ID:
|
Photovoice assessment of integration, health, and healthcare experiences of urban Congolese refugee women in Kampala, Uganda
REFNo: HS2655ES
To generate in-depth, contextual evidence to inform policy and program improvements for Congolese refugee women in Kampala to prevent further marginaliation and negative health outcomes.
|
USA |
2023-02-06 17:19:40 |
2026-02-06 |
Medical and Health Sciences |
Non-Clinical Trial |
Non-degree Award |
|
| View |
|
Sort By: |
|
|
|
| |
|